BioForce Nanosciences Inc., of Ames, Iowa, was awarded a patent titled "Method and Apparatus for Solid State Molecular Analysis." It includes claims encompassing nanoscale arrays useful in identifying target materials or for characterizing molecular interaction events.
Collegium Pharmaceutical Inc., of Hingham, Mass., was issued U.S. Patent No. 6,500,457 B1 titled "Oral Pharmaceutical Dosage Forms for Pulsatile Delivery of An Antiarrhythymic Agent." It relates to methods for pharmaceutical dosage forms that provide for once-daily, pulsatile delivery of Sotalol HCL, a widely used Class III antiarrhythmic.
DOR BioPharma Inc., of Lake Forest, Ill., said the University of Texas Southwestern Medical Center at Dallas was granted U.S. Patent No. 6,566,500, with claims covering mutations in one of the two sites of ricin A chain that are responsible for ricin's toxicity. UT Southwestern licenses the patent, which contains claims relating to structural modifications of ricin A chain that abolish vascular leak syndrome.
GlycoDesign Inc., of Toronto, was issued two patents covering its ATH technology, a covalent complex between an active form of heparin (H) and antithrombin (AT). U.S. Patent No. 6,562,781 includes claims to ATH per se, a process for preparing the antithrombotic and a pharmaceutical preparation made of it, while U.S. Patent No. 6,491,965 covers ATH for use in medical or prosthetic devices, and medical or prosthetic devices comprising ATH.
Kaleidos Pharma Inc., of Seattle, received a notice of allowance for a patent application to cover the use of certain therapeutic compounds, including its lead drug candidate, TGF alpha, for the prevention and treatment of gastrointestinal mucositis, a painful and debilitating side effect associated with cytotoxic or immune-suppressing therapies such as chemotherapeutic drugs.
Novogen Ltd., of Stamford, Conn., was granted a U.S. patent for the use of its isoflavone technology in treating symptoms of menopause and premenstrual syndrome. It applies to the isoflavones genistein, daidzein, formononetin and biochanin.
Oncolytics Biotech Inc., of Calgary, Alberta, received U.S. Patent No. 6,565,831 titled "Method of Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders." It covers the co-administration of the virus with immune suppressing agents such as cyclosporin, while additional claims cover the use of the virus in combination with conventional therapeutic agents and treatments such as surgery, chemotherapy, and radiation therapy.